Barometer Capital Management Inc. increased its position in Johnson & Johnson (NYSE:JNJ) by 6,927.5% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 140,550 shares of the company’s stock after purchasing an additional 138,550 shares during the period. Johnson & Johnson accounts for about 1.9% of Barometer Capital Management Inc.’s investment portfolio, making the stock its 16th biggest holding. Barometer Capital Management Inc.’s holdings in Johnson & Johnson were worth $18,593,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Lynch & Associates IN grew its stake in Johnson & Johnson by 0.9% in the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after purchasing an additional 841 shares in the last quarter. Burke & Herbert Bank & Trust Co. grew its stake in Johnson & Johnson by 2.6% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after purchasing an additional 1,218 shares in the last quarter. Oakbrook Investments LLC grew its stake in Johnson & Johnson by 7.4% in the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after purchasing an additional 9,375 shares in the last quarter. Trexquant Investment LP acquired a new position in Johnson & Johnson in the first quarter worth about $1,731,000. Finally, Paradigm Financial Advisors LLC grew its stake in Johnson & Johnson by 17.1% in the first quarter. Paradigm Financial Advisors LLC now owns 2,640 shares of the company’s stock worth $328,000 after purchasing an additional 386 shares in the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.24% during midday trading on Friday, reaching $131.44. The company had a trading volume of 1,791,096 shares. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The company has a market capitalization of $352.78 billion, a P/E ratio of 22.24 and a beta of 0.79. The firm’s 50 day moving average price is $132.79 and its 200-day moving average price is $129.43. Johnson & Johnson also was the recipient of some unusual options trading on Wednesday. Traders bought 11,192 put options on the stock. This is an increase of 244% compared to the average daily volume of 3,249 put options.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.74 EPS. Analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 56.76%.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Barometer Capital Management Inc. Boosts Position in Johnson & Johnson (JNJ)” was published by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/22/barometer-capital-management-inc-boosts-position-in-johnson-johnson-jnj.html.

JNJ has been the subject of a number of research reports. BTIG Research downgraded Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 target price for the company. in a research note on Friday, July 21st. Atlantic Securities downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price for the company. in a research note on Friday, July 21st. Alembic Global Advisors downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Finally, Vetr downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a research note on Monday. Five analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $135.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.